Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations

被引：17

作者：

Langrand-Escure, J. ^{[1
]}

de Crevoisier, R. ^{[2
,3
]}

Llagostera, C. ^{[4
]}

Crehange, G. ^{[5
]}

Delaroche, G. ^{[1
]}

Lafond, C. ^{[2
,3
]}

Bonin, C. ^{[6
]}

Bideault, F. ^{[5
]}

Sargos, P. ^{[7
]}

Belhomme, S. ^{[7
]}

Pasquier, D. ^{[8
]}

Latorzeff, I ^{[9
]}

Supiot, S. ^{[4
]}

Hennequin, C. ^{[10
]}

机构：

[1] Inst Cancerol La Loire Lucien Neuwirth, 180 Bis,Ave Albert Raimond, F-42270 St Priest En Jarez, France

[2] Ctr Eugene Marquis, Dept Radiotherapie, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France

[3] Inserm 1099, LTSI, 263 Ave Gen Leclerc, F-35042 Rennes, France

[4] Inst cancerol Ouest Rene Gauducheau, Blvd Jacques Monod, F-44805 St Herblain, France

[5] Ctr Georges Francois Leclerc, Dept Radiotherapie, 1 Ave Prof Marion, F-21000 Dijon, France

[6] CHU Jean Minjoz, Serv Radiotherapie, 3 Blvd Alexandre Fleming, F-25000 Besancon, France

[7] Inst Bergonie, Dept Radiotherapie, 229 Cours Argonne, F-33000 Bordeaux, France

[8] Ctr Oscar Lambret, Dept Radiotherapie, 3 Rue Frederic Combemale, F-59020 Lille, France

[9] Clin Pasteur, Dept Oncol Radiotherapie, Bat Atrium,1 Rue Petite Vitesse, F-31300 Toulouse, France

[10] Hop St Louis, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France

来源：

CANCER RADIOTHERAPIE | 2018年 / 22卷 / 02期

关键词：

Prostate cancer; Hypofractionation; Radiotherapy; Image-guided radiation therapy; Recommendations; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; III RANDOMIZED-TRIAL; RADIATION-THERAPY; NON-INFERIORITY; PHASE-3; TRIAL; ACUTE TOXICITY; HIGH-RISK; ADENOCARCINOMA;

D O I：

10.1016/j.canrad.2017.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).

引用

页码：193 / 198

页数：6

共 50 条

[21] Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
Yamazaki, Hideya
Suzuki, Gen
Aibe, Norihiro
Shimizu, Daisuke
Kimoto, Takuya
Masui, Koji
Yoshida, Ken
Nakamura, Satoaki
Hashimoto, Yasutoshi
Okabe, Haruumi
CANCERS, 2022, 14 (01)
[22] Gemcitabine and cisplatin after radical bladder cancer in an adjuvant setting:: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centres
Flechon, Aude
Fizazi, Karim
Gourgou-Bourgade, Sophie
Theodore, Christine
Beuzeboc, Philippe
Geoffrois, Lionel
Mottet, Nicolas
Chevreau, Christine
Culine, Stephane
ANTI-CANCER DRUGS, 2006, 17 (06) : 705 - 708
[23] First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)
Ravaud, A.
Oudard, S.
Gravis-Mescam, G.
Sevin, E.
Zanetta, S.
Theodore, C.
de Fromont, M.
Oukhatar, C. Mahier-Ait
Chene, G.
Escudier, B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[24] FIRST LINE SUNITINIB IN TYPE I AND II PAPILLARY RENAL CELL CARCINOMA (PRCC): SUPAP- A PHASE II STUDY OF THE FRENCH GENITO-URINARY GROUP (GETUG) AND THE GROUP OF EARLY PHASE TRIALS (GEP)
Ravaud, A.
Oudard, S.
De Fromont, M.
Chevreau, C.
Gravis, G.
Zanetta, S.
Theodore, C.
Jimenez, M.
Sevin, E.
Escudier, B.
ANNALS OF ONCOLOGY, 2012, 23 : 263 - 263
[25] Searching for Optimal Dose-Volume Constraints to Reduce Rectal Toxicity after Hypofractionated Radiotherapy for Prostate Cancer
Faria, S.
Joshua, B.
Patrocinio, H.
Dal Pra, A.
Cury, F.
Velly, A. M.
Souhami, L.
CLINICAL ONCOLOGY, 2010, 22 (10) : 810 - 817
[26] dose escalation in hypofractionated radiotherapy in prostate cancer : early and late toxicity
Quintin, K.
Crehange, G.
Graff, P.
Krhili, S.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1190 - S1191
[27] dose effects due to interfractional variability for hypofractionated radiotherapy of prostate cancer
Splinter, M.
Sachpazidis, I.
Bostel, T.
Haering, P.
Lang, C.
Grosu, A.
Debus, J.
Baltas, D.
Nicolay, N. H.
RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S616 - S617
[28] Exploring the Role of Angiotensin Converting Enzyme Inhibitors in Genito-Urinary Toxicity Following Curative Radiotherapy for Bladder Cancer
Devi, A.
Olowofela, A.
Lodhi, T.
Hoskin, P.
Ballas, L. K.
Choudhury, A.
Kerns, S. L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E524 - E524
[29] Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors:: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T9313P)
Culine, S.
Kerbrat, P.
Kramar, A.
Theodore, C.
ChevreauU, C.
Geoffrois, L.
Bui, N. B.
Peny, J.
Caty, A.
Delva, R.
Biron, P.
Fizazi, K.
Bouzy, J.
Droz, J. P.
ANNALS OF ONCOLOGY, 2007, 18 (05) : 917 - 924
[30] OAR dose constraints consensus in hypofractionated breast cancer radiotherapy is urgently needed!
Ben Amor, R.
Bohli, M.
Aissaoui, D.
Yahiaoui, J.
Hamdoun, A.
Kochbati, L.
RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1665 - S1666

← 1 2 3 4 5 →